BingX Labs Marks One Year of Web3 & AI Innovation with $16Million in Strategic Investments
Since its launch in 2024, BingX Labs has committed $16 million in investments across high-impact projects and protocols such as Babylon and StakeStone, alongside strategic collaborations with leading partners including IOSG, Kaia foundation, and Hackquest to support broader Web3 and AI ecosystem growth. These partnerships exemplify BingX Labs' approach — fostering strategic collaborations with the builders of core infrastructure for the next phase of Web3 and AI adoption.
Beyond financial backing, BingX Labs has become a hub of research and innovation. The Labs team is actively exploring key emerging sectors such as RWA (Real-World Assets), DeFi, and AI agents. With regular webinars and developer meetups, BingX Labs connects with global builder communities to share insights and collaborate on the next wave of technological breakthroughs. BingX Labs has also reinforced its position as a key player in the Web3 and AI space by sponsoring and attending major international events like Consensus and the Token 2049.
Vivien Lin, Head of BingX Labs and Chief Product Officer at BingX, commented:"In its first year, BingX Labs has evolved into more than an investment platform — it is a catalyst for the next generation of Web3 and AI innovation. By combining deep research, strategic partnerships, and strong developer engagement, we are building the infrastructure to support breakthrough projects that will shape the future of AI and decentralized technology. Looking ahead, our commitment to empowering developers and partners in these transformative sectors will continue to be our guiding principle."
Looking ahead, BingX Labs plans to deepen its research, expand partnerships, and explore new opportunities, especially in AI-powered decentralized applications, with a continued focus on uncovering the next wave of transformative projects.
About BingX
Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
19 minutes ago
- Cision Canada
Trulieve Announces August 2025 Event Participation
TALLAHASSEE, Fla., Aug. 8, 2025 /CNW/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned event participation in August. Canaccord Genuity 45th Annual Growth Conference, August 12, 2025: Vice President of Investor Relations Christine Hersey will participate in a fireside chat and investor meetings. Information about our events, links to events where available, and slide presentations can be found at: About Trulieve Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Facebook: @Trulieve Instagram: @Trulieve X: @Trulieve Investor Contact Christine Hersey, Vice President of Investor Relations +1 (424) 202-0210 [email protected] Media Contact Phil Buck, APR, Corporate Communications Manager +1 (406) 370-6226 [email protected] SOURCE Trulieve Cannabis Corp.
Cision Canada
19 minutes ago
- Cision Canada
Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE) Français
ANDEMBRY is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in people with HAE The authorization of ANDEMBRY expands CSL's HAE franchise and underscores the company's commitment to delivering innovative medicines to the HAE community OTTAWA, Canada, Aug. 8, 2025 /CNW/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that Health Canada has granted a marketing authorization for ANDEMBRY ® (garadacimab) for routine prevention of attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ANDEMBRY is a monoclonal antibody designed to target activated FXII (FXIIa), a plasma protein at the top of the HAE cascade that plays a key role in attacks of swelling in people with HAE. ANDEMBRY reinforces CSL's decades-long commitment to advancing innovation for the HAE community and is authorized with a prefilled pen for subcutaneous self-injection. "As the first monoclonal antibody discovered and developed entirely by CSL, ANDEMBRY is a reflection of our commitment to delivering innovative treatment options for the patients who need them most," said Bill Mezzanotte, MD, Executive Vice President, Head of R&D, CSL. "This approval marks a major step forward in HAE care, building on our more than 40-year legacy in HAE research and treatment optimization to offer people living with this life-threatening condition long-term control over their disease along with a convenient administration method." HAE is a rare, chronic, and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of angioedema. Attacks of HAE are often painful and can affect multiple sites of the body, including the abdomen, larynx, face, and extremities. ANDEMBRY inhibits the top of the HAE cascade while other HAE therapies target downstream mediators. "Health Canada's authorization of ANDEMBRY represents a significant advancement in the treatment of HAE," said Dr. Stephen Betschel, Chair of the Canadian Hereditary Angioedema Network. "This new therapy, which targets factor XIIa, offers a promising approach to preventing HAE attacks. By addressing the underlying mechanisms of HAE, ANDEMBRY provides an important option for patients to reduce the frequency of their attacks of angioedema. Having a new treatment option will further enhance our ability to help our patients manage their HAE effectively." The Health Canada authorization is based on data from the pivotal placebo-controlled Phase 3 VANGUARD trial evaluating the efficacy and safety of ANDEMBRY. The pivotal study (The Lancet, April 2023) demonstrated that treatment with ANDEMBRY: Reduced HAE attacks by a median of more than 99 percent and a reduced least squares mean of 89.2 percent, compared to placebo. Led to 62 percent of ANDEMBRY-treated patients remaining attack-free throughout the treatment period. The most common adverse reactions in the pivotal trial were injection site erythema, injection site bruising, injection site pruritus, injection site urticaria, headache, and abdominal pain. A published interim analysis (Allergy, Oct 2024) of the ongoing open-label extension study (median ANDEMBRY exposure of 13.8 months) showed that ANDEMBRY has a favorable long-term safety profile and provides sustained reductions in HAE attacks. "We are pleased to see Health Canada's authorization of ANDEMBRY for HAE and look forward to its availability in Canada," said Michelle Cooper, President, HAE Canada. "As the first treatment to target the top of the HAE cascade, this therapy represents a significant advancement in preventing HAE attacks. We believe it will provide meaningful benefits to the HAE community in Canada." This regulatory approval for ANDEMBRY is another crucial step in building toward the global availability of ANDEMBRY, which was recently approved in Australia, the United Kingdom (UK), the European Union (EU), Japan, Switzerland, and the United States (US). About HAE HAE is a rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE is caused by deficient or dysfunctional C1-INH, a protein in the blood that helps to control inflammation. Inadequate amounts of properly functioning C1-INH can lead to the accumulation of fluid in body tissues, causing considerable swelling referred to as angioedema. HAE attacks can affect many parts of the body, including the face, abdomen, larynx, and extremities. Patients who have abdominal attacks of HAE can experience extreme pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face or throat can result in airway closure, asphyxiation and, if left untreated, death. About ANDEMBRY ANDEMBRY is a novel monoclonal antibody inhibiting factor XIIa (anti-FXIIa mAb) that has completed the Phase 3 pivotal study as a once-monthly subcutaneous prophylactic treatment for attacks related to HAE, a form of bradykinin-mediated angioedema. ANDEMBRY is CSL's first homegrown recombinant monoclonal antibody to gain Health Canada approval. It was discovered and optimized by scientists at CSL's Bio21-based research site, with formulation and manufacturing for the clinical programs completed at the CSL Broadmeadows Biotech Manufacturing Facility. ANDEMBRY uniquely inhibits the plasma protein, FXIIa. FXII is the first protein activated in the HAE pathway, initiating the cascade of events leading to an HAE attack. By targeting activated FXII (FXIIa), ANDEMBRY inhibits this cascade at the top as compared to other HAE therapies that target downstream mediators. About t he VANGUARD Trial The multicenter, randomized, double-blind, parallel-group VANGUARD trial evaluated the efficacy and safety of ANDEMBRY, a first-in-class monoclonal antibody, as a prophylactic treatment for patients with hereditary angioedema. Patients aged 12 years and older with HAE type I or II underwent screening and a run-in study period to verify a baseline attack rate. Patients were randomized 3:2 to receive a loading dose of 400 mg followed by 200 mg of ANDEMBRY monthly (n=39) or volume matched placebo monthly (n=25) subcutaneously. After the six-month treatment period, patients were given the opportunity to continue into the open-label extension study, which is currently ongoing. The ongoing open-label extension of the Phase 3 VANGUARD study is evaluating the long-term safety and efficacy of ANDEMBRY (200 mg monthly) for the prophylactic treatment of hereditary angioedema attacks. Important Information for Canada For more information and a complete risk/benefit profile, please refer to the Product Monograph available here. About CSL CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat Hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL, visit Media Contact Valerie Bomberger, CSL Office: +1 610-291-5388 Mobile: +1 267-280-3829 Email: [email protected] Etanjalie Ayala CSL Behring Mobile: +1 610 297 1069 Email: [email protected] Greg Healy CSL Mobile: +1 610-906-4564 Email: [email protected] In Australia: Kim O'Donohue CSL Mobile: +61 449 884 603 Email: [email protected] Brett Foley CSL Mobile: +61 461 464 708 Email: [email protected] Investors Contact Chris Cooper CSL Email: [email protected] +61 455 022 740 SOURCE CSL
Cision Canada
19 minutes ago
- Cision Canada
VISIBLE GOLD MINES APPOINTS VERONIQUE LABERGE AS NEW CFO
ROUYN-NORANDA, QC, Aug. 8, 2025 /CNW/ - Visible Gold Mines Inc. (TSXV: VGD) (Frankfurt: 3V41) (the " Corporation") is pleased to announce the appointment of Ms. Veronique Laberge as the new Chief Financial Officer of the Corporation. Ms. Laberge will replace the current CFO per interim, Martin Dallaire. Mr. Dallaire remains as Chief Executive Officer of the Corporation. Ms. Veronique Laberge is a chartered professional accountant and holder of the title of auditor. With more than 19 years of experience in professional practice, she specialized in certification mandates, general accounting and has been working as a fractional CFO for multiple public and private companies since 2018. The Board of Directors of the Corporation wishes to welcome Ms Veronique Laberge. About Visible Gold Mines Visible Gold Mines is a corporation focused on gold in the Chibougamau area and lithium in the James Bay region in the province of Québec. Visible Gold Mines has 37,155,164 common shares issued and outstanding.
